06622.HK
Zhaoke Ophthalmology Limited
HKSE · Healthcare · Biotechnology · CN
HKD 2.02
−2.42%Oct 27, 2026, 00:35 UTC
The Australian Therapeutic Goods Administration granted GMP certification to Zhaoke Ophthalmology Ltd.’s production base in Nansha, Guangzhou.
Sep 23, 2026, 20:13 UTC
Evofem Biosciences signed a manufacturing and supply agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Co. Ltd. for the manufacture and supply of PHEXX.
Sep 7, 2026, 02:20 UTC
Zhaoke Ophthalmology announced that its YUVEZZI eye drop reached the primary endpoint in a Phase II clinical study in China for presbyopia patients, and plans to advance to Phase III clinical trials.
Source:Aug 12, 2026, 09:02 UTC
Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.
Source: